Corbus Pharmaceu Stock Price, News & Analysis

Corbus Pharmaceuticals (NASDAQ: CRBP) announced that CEO Yuval Cohen, Ph.D. will participate in a Fireside Chat at the Piper Sandler Virtual Oncology Symposium on October 9-10, 2025. The Corbus session is scheduled for October 9, 2025 at 10:00AM ET and will be hosted by Biren Amin, Managing Director, Piper Sandler Healthcare Equity Research.

Piper Sandler clients can register through their representative. The participation is a presentation event and does not include new financial guidance or clinical readout details.

Corbus Pharmaceuticals (NASDAQ: CRBP) announced it will host a Key Opinion Leader (KOL) event at ESMO Congress 2025 in Berlin, Germany. The event will present dose optimization data from the Phase 1/2 clinical study of CRB-701 involving over 100 patients with head and neck squamous cell carcinoma (HNSCC), cervical, or metastatic urothelial tumors.

The KOL panel will feature prominent experts from leading institutions including the University of Chicago, Dana-Farber Cancer Institute, and Sarah Cannon Research Institute. The event is scheduled for October 19, 2025, at 10AM CEST, with both in-person and virtual attendance options available. The clinical trial data will also be presented as a poster at ESMO 2025.

Corbus Pharmaceuticals (NASDAQ: CRBP) has received Fast Track designation from the FDA for its antibody drug conjugate CRB-701 in treating recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). This marks the second Fast Track designation for CRB-701, following its December 2024 designation for relapsed/refractory metastatic cervical cancer.

CRB-701 is a next-generation Nectin-4 targeting ADC featuring a site-specific, cleavable linker and a precise drug antibody ratio of 2 using MMAE payload. The company is conducting a Phase 1/2 clinical trial evaluating CRB-701's safety, pharmacokinetics, and efficacy in advanced solid tumors with high Nectin-4 expression. Initial dose optimization data will be presented at ESMO 2025 on October 19, 2025.

Corbus Pharmaceuticals (NASDAQ: CRBP) has reported Q2 2025 financial results and provided updates on its three clinical programs. The company posted a net loss of $17.7 million ($1.44 per share) and holds $116.6 million in cash, sufficient to fund operations through Q2 2027.

Key developments include: CRB-701 (Nectin-4 targeting ADC) Phase 1/2 dose expansion data to be presented at ESMO 2025, with Fast Track designation for cervical cancer treatment; CRB-913 (obesity drug) has initiated its 7-day MAD study phase with SAD/MAD data expected later this year; and CRB-601 (anti-αvβ8 integrin mAB) is progressing with dose escalation data expected in Q4 2025.

Corbus Pharmaceuticals (NASDAQ: CRBP) announced the acceptance of their abstract for presentation at the ESMO Congress 2025 in Berlin. The presentation will showcase updated clinical data from their Phase 1/2 study of CRB-701, a next-generation Nectin-4-targeting antibody-drug conjugate.

The study (NCT06265727) is evaluating CRB-701 in patients with advanced solid tumors expressing Nectin-4. Part A evaluated four doses (1.8-4.5 mg/kg Q3W), with ongoing dose optimization in Part B at 2.7 and 3.6 mg/kg cohorts in HNSCC, cervical, and mUC tumors. The company expects to identify a recommended Phase 2 dose in Q4 2025.

Corbus Pharmaceuticals (NASDAQ: CRBP) has initiated the multiple ascending dose (MAD) portion of its Phase 1 trial for CRB-913, a highly peripherally restricted CB1 inverse agonist targeting obesity treatment. This advancement follows the successful completion of the single ascending dose (SAD) study's safety and pharmacokinetics analysis.

The MAD study will evaluate once-daily dosing of CRB-913 for 7 days in healthy volunteers, focusing on safety, tolerability, and pharmacokinetics. Notably, no treatment-related neuropsychiatric events were observed during the SAD portion, even at doses significantly higher than those expected for clinical efficacy.

The company has outlined a clear development timeline: The SAD/MAD portion is scheduled for completion in Q3 2025, followed by a Phase 1b dose-range finding study in obese individuals starting in Q4 2025, with completion expected in the second half of 2026.

Corbus Pharmaceuticals (NASDAQ: CRBP) has initiated the PD-1 combination arm of its Phase 1 study for CRB-701, dosing its first participant. The combination therapy involves CRB-701 with Keytruda® (pembrolizumab) at doses of 2.7 mg/kg and 3.6 mg/kg.

The three-part Phase 1 study (NCT06265727) focuses on advanced solid tumors with high Nectin-4 expression, with over 100 participants dosed in the monotherapy cohort. The study prioritizes Head and Neck Squamous Cell Carcinoma (HNSCC) and cervical cancer. The company plans to provide a data update and establish the recommended Phase 2 dose in Q4 2025.

Corbus Pharmaceuticals (NASDAQ: CRBP) announced its participation in the upcoming Piper Sandler 3rd Annual Virtual Obesity Symposium on June 26, 2025. CEO Yuval Cohen, Ph.D. will engage in a fireside chat at 10:00 a.m. ET, hosted by Biren Amin, Managing Director of Healthcare Equity Research at Piper Sandler.

The symposium will feature presentations from key opinion leaders and fireside chats with companies developing obesity therapeutics. The event is exclusively available to Piper Sandler clients through their representatives.

Corbus Pharmaceuticals (NASDAQ: CRBP) has announced that CEO Yuval Cohen will deliver a corporate presentation at the upcoming Jefferies Global Healthcare Conference in New York. The presentation is scheduled for June 4, 2025, at 4:55 p.m. ET. In addition to the presentation, Dr. Cohen will participate in one-on-one meetings with investors during the conference, which runs from June 3-5, 2025. A webcast of the presentation will be available for interested parties.